A recent study found that mycophenolate mofetil is an effective alternative for the treatment of systemic scleroderma with interstitial lung disease, resulting in possible long-term improvement. According to Aryeh Fischer, MD, this new research points to the future expansion of treatment options…
Richard Quinn is an award-winning journalist with 15 years’ experience. He has worked at the Asbury Park Press in N.J. and The Virginian-Pilot in Norfolk, Va., and currently is managing editor for a leading commercial real estate publication. His freelance work has appeared in The Jewish State, The Hospitalist, The Rheumatologist, ACEP Now and ENT Today. He lives in New Jersey with his wife, new son and three cats.
Articles by Richard Quinn
A Long Way to Go: Treating Pain in Patients with Inflammation
Subjectivity and the differences in how patients with autoimmune and other diseases perceive pain make the study and treatment of pain difficult. But Yvonne Lee, MD, says future advances in neuroimaging may aid in the objective study of pain and innovative treatments…
From the Expert: Don’t Forget to Vaccinate Immuncompromised Patients
Preventing infection in immunocompromised patients is challenging, especially with the increased use of biologic treatments, which have been known to reactivate latent infections, such as the herpes zoster virus. Nicolas Issa, MD, discusses recent vaccination research and prevention techniques to help this patient group avoid infection…
Under Patient Control: Is Diet a Risk Factor for RA?
Two recent studies have linked diet to an increased risk for developing rheumatoid arthritis. According to one expert, this information could prove to be pivotal knowledge for individuals already at a greater risk of developing the disease…
From the Expert: Patient Access Is Key for Biosimilars in Development to Be Effective
Recent research by Michael Weinblatt, MD, and colleagues has demonstrated that a biosimilar derived from adalimumab is both effective and safe for treating patients with rheumatoid arthritis. But Dr. Weinblatt says, the benefits of such biosimilars hinge on cost and patient access…
Careful Collaboration: 5 Tips for Participating in Clinical Trials
For rheumatologists, research is important, but some clinical trials may not be worth collaborating on. In a recent interview, Hermine Brunner, MD, MSc, MBA, FACR, outlined important considerations to make when deciding to participate in a clinical trial to ensure a good fit…
From the Expert: New Insights into Treating Pregnant Patients with Rheumatic Disease
The approach of under-treating rheumatic disease in pregnant patients is changing, according to Bonnie Lee Bermas, MD. Dr. Bermas discusses with The Rheumatologist the need for more research on how drugs affect this patient group, and how timing of conception and disease stability play important roles in the safe outcomes of mother and infant…
From the Expert: Insight into the Intersection of Cancer & Autoimmunity
Research by Dr. Anthony Rosen, MD, and colleagues found a link between cancer and scleroderma, suggesting the immune system may edit cancer cells. In an interview with The Rheumatologist, Dr. Rosen explores the meaning of this finding and its potential…
The Effect of Tofacitinib on Live Vaccine Responses
New research indicates that vaccination for the herpes zoster virus in patients with rheumatoid arthritis starting tofacitinib appears to be both safe and useful. Rheumatologists may want to check the patient’s pre-existing immunity status prior to administering the vaccine…
How Technology Can Benefit Rheumatology Practices
Electronic health records, mobile apps, telemedicine, patient portals—new technologies offer rheumatologists more efficiency and patients greater knowledge. Here are a few ways these technologies can aid a practice…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 16
- Next Page »